gpASIT+ clinical trials
How each study uses gpASIT+ is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- gpASIT+TM
- 8
Studies by the year they started
8 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses gpASIT+ is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic RhinoconjunctivitisStatus unknownPhase 3ASIT Biotech S.A.NCT03724240Written as gpASIT+TM
- Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic RhinoconjunctivitisCompletedPhase 3BioTech Tools S.A.NCT02560948Written as gpASIT+TM
- Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TMCompletedPhase 2BioTech Tools S.A.NCT02156791Written as gpASIT+TM
- Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic RhinitisCompletedPhase 1BioTech Tools S.A.NCT00813046Written as gpASIT+TM
- Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating AdjuvantCompletedPhase 2BioTech Tools S.A.NCT01506375Written as gpASIT+TM
- Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic RhinoconjunctivitisCompletedPhase 2BioTech Tools S.A.NCT01308021Written as gpASIT+TM
- Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic RhinoconjunctivitisCompletedPhase 1/2BioTech Tools S.A.NCT00833066Written as gpASIT+TM
- Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen RhinoconjunctivitisCompletedPhase 1BioTech Tools S.A.NCT01111279Written as gpASIT+TM